To amend the Public Health Service Act with respect to the Living Organ Donation Reimbursement Program.

1) What happened and its current status: Rep. DelBene (D-WA) introduced HR7868 on March 9, 2026, with two cosponsors (Rep. Miller of WV and Rep. Schrier). The bill was referred to the House Energy and Commerce Committee and the Ways and Means Committee. Status is 'referred to committee' — early stage. No markup, no vote, no Senate companion bill identified. 2) The money trail — authorization vs. appropriation: The bill amends Section 377 of the Public Health Service Act to raise the maximum reimbursement for living organ donors to $10,000 for FY2027 (indexed to CPI thereafter) and expands income eligibility to 700% of poverty line. This is an authorization bill — it sets a ceiling but does not appropriate actual dollars. The Living Organ Donation Reimbursement Program is a grant program administered by HRSA; actual funding requires a separate appropriations bill. The bill text does not specify a total program funding amount — it sets per-donor caps. The CBO score would determine budget impact. 3) Structural winners and losers: The bill structurally benefits companies providing donor diagnostic testing services — Labcorp ($LH) and Quest Diagnostics ($DGX) are the clearest beneficiaries as donors require HLA typing, blood work, and post-operative monitoring. A larger pool of reimbursed donors means more test volume. Device makers Medtronic and Stryker have only tangential exposure — the reimbursement is for donor travel, lodging, lost wages, and medical expenses, not for hospital procurement of surgical devices. The link to device sales is weak and requires multiple inferential steps. 4) Real market data analysis (as of April 30, 2026): All four stocks are in a broad downtrend over the past 30 days. $LH at $258.01 is down 3.3% in 30 days and trading near the bottom half of its 52-week range ($235.81-$293.72). $DGX at $190.49 is down 2.8% in 30 days. at $79.21 is down 8.59% in 30 days and is essentially at its 52-week low ($78.91). at $314.40 is down 4.32% in 30 days and near its 52-week low ($311.31). None of these price movements correlate with HR7868 — the bill was introduced March 9 and the price moves are driven by broader market factors. The downtrend across healthcare suggests sector-wide selling pressure. 5) Timeline and remaining steps: The bill must pass through both House committees (Energy & Commerce, Ways and Means), then the full House, then the Senate (no companion bill yet), then be signed into law. Even if enacted, actual funding requires an appropriation. Given the modest scope ($10,000 per donor cap), the probability of significant market impact is low in the near term. Cosponsorship by two Democrats and one Republican (Miller) gives it bipartisan sponsorship, but early stage with only 4 total actions.